Cai Yu-Long, Song Pei-Pei, Tang Wei, Cheng Nan-Sheng
Department of Bile Duct Surgery, West China Hospital, Sichuan University, Chengdu, Sichuan Province, China Graduate School of Frontier Sciences, The University of Tokyo, Kashiwa-shi, Chiba, Japan.
Medicine (Baltimore). 2016 Jun;95(24):e3941. doi: 10.1097/MD.0000000000003941.
The main obstacle to achieving an R0 resection after a major hepatectomy is inability to preserve an adequate future liver remnant (FLR) to avoid postoperative liver failure (PLF). Associating liver partition and portal vein ligation for staged hepatectomy (ALPPS) is a novel technique for resecting tumors that were previously considered unresectable, and this technique results in a vast increase in the volume of the FLR in a short period of time. However, this technique continues to provoke heated debate because of its high mortality and morbidity.The evolution of ALPPS and its advantages and disadvantages have been systematically reviewed and evaluated in accordance with current evidence. Electronic databases (PubMed and Medline) were searched for potentially relevant articles from January 2007 to January 2016.ALPPS has evolved into various modified forms. Some of these modified techniques have reduced the difficulty of the procedure and enhanced its safety. Current evidence indicates that the advantages of ALPPS are rapid hypertrophy of the FLR, the feasibility of the procedure, and a higher rate of R0 resection in comparison to other techniques. However, ALPPS is associated with worse major complications, more deaths, and early tumor recurrence.Hepatobiliary surgeons should carefully consider whether to perform ALPPS. Some modified forms of ALPPS have reduced the mortality and morbidity of the procedure, but they cannot be recommended over the original procedure currently. Portal vein embolization (PVE) is still the procedure of choice for patients with a tumor-free FLR, and ALPPS could be used as a salvage procedure when PVE fails. More persuasive evidence needs to be assembled to determine whether ALPPS or two-stage hepatectomy (TSH) is better for patients with a tumor involving the FLR. Evidence with regard to long-term oncological outcomes is still limited. More meticulous comparative studies and studies of the 5-year survival rate of ALPPS could ultimately help to determine the usefulness of ALPPS. Indications and patient selection for the procedure need to be determined.
肝大部切除术后实现R0切除的主要障碍是无法保留足够的未来肝脏残余量(FLR)以避免术后肝衰竭(PLF)。联合肝脏分隔和门静脉结扎分期肝切除术(ALPPS)是一种用于切除先前被认为无法切除的肿瘤的新技术,该技术可在短时间内使FLR体积大幅增加。然而,由于其高死亡率和发病率,该技术仍引发激烈争论。根据现有证据,对ALPPS的演变及其优缺点进行了系统回顾和评估。检索电子数据库(PubMed和Medline)以查找2007年1月至2016年1月期间可能相关的文章。ALPPS已演变成各种改良形式。其中一些改良技术降低了手术难度并提高了安全性。现有证据表明,ALPPS的优点是FLR快速肥大、手术可行性以及与其他技术相比更高的R0切除率。然而,ALPPS与更严重的主要并发症、更多死亡和早期肿瘤复发相关。肝胆外科医生应仔细考虑是否进行ALPPS。ALPPS的一些改良形式降低了手术的死亡率和发病率,但目前尚不能推荐其优于原始手术。门静脉栓塞术(PVE)仍然是FLR无肿瘤患者的首选手术,当PVE失败时,ALPPS可作为挽救手术。需要收集更有说服力的证据来确定对于FLR受累肿瘤患者,ALPPS还是两阶段肝切除术(TSH)更好。关于长期肿瘤学结果的证据仍然有限。更细致的比较研究和ALPPS 5年生存率的研究最终可能有助于确定ALPPS的实用性。该手术的适应症和患者选择需要确定。